David J. Endicott
board of director
Orexigen Therapeutics
Orexigen
Australia
Biography
David J. Endicott has served as a member of our board of directors since November 2012. Mr. Endicott currently serves as the Chief Operating Officer of Alcon, a division of Novartis. Prior to joining Alcon, Mr. Endicott was President of Hospira Infusion Systems, a Pfizer company. Before joining Hospira, he served as an officer and executive committee member of Allergan where he spent 27 years of his career in commercial leadership roles across Asia and Latin America, Europe, Africa and Middle East, as well as the US, expanding Allergan’s international presence and successfully building new markets focused on medical specialties in the areas of ophthalmology, plastic surgery, dermatology and neurology. Mr. Endicott holds an undergraduate degree in Chemistry from Whitman College, an M.B.A. from the University of Southern California and is a graduate of the Advanced Management Program at the Harvard Business School.
Research Interest
Molecular Biology and Molecular Genetics
